Researchers present results from pivotal cancer trials, including an ADC-Keytruda combination, at the European Society for Medical Oncology Congress on Oct. 22 (Kyle LaHucik for Endpoints News)

October 23, 2023 08:32 AM EDTUpdated 10:59 AM

R&D

In Focus

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

MADRID — When Daiichi Sankyo scientists pushed forward with antibody-drug conjugate research nearly a decade ago, the program had a lot of naysayers, even inside the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Merck’s long-awaited obesity move is an oral GLP-1 from China

Major PBM reforms feature in Congress' year-end spending bill

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

You get an ADC, you get an ADC: Phar­mas bite on on­col­o­gy’s buzzi­est class

News Reporter

Senior Reporter

Sign up to read this article for free.

more like this

You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class